Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence and Food Effect Study of Vadadustat 450 mg vs 150 mg Tablets
NCT03657290Phase 1Completed
- Sponsor
- Akebia Therapeutics
- Start
- Aug 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vadadustat in anemia (3 arms), sponsored by Akebia Therapeutics. Primary endpoints: Area under plasma concentration-time curve from 0 to last quantifiable concentration at 48 hours, Area under plasma concentration-time curve from 0 to infinity at 48 hours and 2 more. Started Aug 2018; status: completed.
02
Drugs
vadadustat
03
Conditions
anemia
Beyond the preview
Go deeper on NCT03657290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03657290.